×
About 6,633 results

ALLMedicine Familial Hypercholesterolemia Center

Research & Reviews  2,557 results

Development and validation of a measure of comprehension of genomic screening-negative ...
https://doi.org/10.1038/s41431-020-0657-1
European Journal of Human Genetics : EJHG; Henderson GE, Ewing M et. al.

May 25th, 2020 - To realize the promise of population genomic screening for rare medically actionable conditions, critical challenges in the return of normal/negative results must be understood and overcome. Our study objective was to assess the functioning of a n...

Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subj...
https://doi.org/10.1016/j.jacc.2020.03.057
Journal of the American College of Cardiology; Beheshti SO, Madsen CM et. al.

May 21st, 2020 - Despite the greater prevalence of familial hypercholesterolemia (FH) in subjects with ischemic heart disease (IHD), premature IHD, and severe hypercholesterolemia (low-density lipoprotein ≥190 mg/dl), overall prevalence estimates are not available...

Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans.
https://doi.org/10.1016/j.jacc.2020.03.058
Journal of the American College of Cardiology; Kastelein JJP, Reeskamp LF et. al.

May 21st, 2020 - Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans.|2020|Kastelein JJP,Reeskamp LF,Hovingh GK,|

Assessment of medical intern's knowledge, awareness and practice of familial hyperchole...
https://doi.org/10.1186/s12944-020-01266-y
Lipids in Health and Disease; Alzahrani SH, Bima A et. al.

May 20th, 2020 - Familial Hypercholesterolemia (FH) is a serious under-diagnosed disease characterized by raised low-density lipoprotein cholesterol (LDL-C) and premature coronary artery diseases (CAD). The scarcity of FH reported patients in Saudi Arabia indicate...

What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
https://doi.org/10.1016/j.tcm.2020.04.001
Trends in Cardiovascular Medicine; Brunham LR, Mancini GBJ

May 14th, 2020 - What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?|2020|Brunham LR,Mancini GBJ,|

see more →

Guidelines  5 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  315 results see all →

Clinicaltrials.gov  3,287 results

Development and validation of a measure of comprehension of genomic screening-negative ...
https://doi.org/10.1038/s41431-020-0657-1
European Journal of Human Genetics : EJHG; Henderson GE, Ewing M et. al.

May 25th, 2020 - To realize the promise of population genomic screening for rare medically actionable conditions, critical challenges in the return of normal/negative results must be understood and overcome. Our study objective was to assess the functioning of a n...

Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subj...
https://doi.org/10.1016/j.jacc.2020.03.057
Journal of the American College of Cardiology; Beheshti SO, Madsen CM et. al.

May 21st, 2020 - Despite the greater prevalence of familial hypercholesterolemia (FH) in subjects with ischemic heart disease (IHD), premature IHD, and severe hypercholesterolemia (low-density lipoprotein ≥190 mg/dl), overall prevalence estimates are not available...

Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans.
https://doi.org/10.1016/j.jacc.2020.03.058
Journal of the American College of Cardiology; Kastelein JJP, Reeskamp LF et. al.

May 21st, 2020 - Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans.|2020|Kastelein JJP,Reeskamp LF,Hovingh GK,|

Welchol - colesevelam hydrochloride tablet, film coated-Daiichi Sankyo Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a06d3b2-7229-4398-baba-5d0a72f63821

May 20th, 2020 - WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia (1.1). reduce LDL-C levels in boys and postmenarchal girls, 10 to...

Assessment of medical intern's knowledge, awareness and practice of familial hyperchole...
https://doi.org/10.1186/s12944-020-01266-y
Lipids in Health and Disease; Alzahrani SH, Bima A et. al.

May 20th, 2020 - Familial Hypercholesterolemia (FH) is a serious under-diagnosed disease characterized by raised low-density lipoprotein cholesterol (LDL-C) and premature coronary artery diseases (CAD). The scarcity of FH reported patients in Saudi Arabia indicate...

see more →

News  465 results

Alirocumab Effective in Homozygous FH
https://www.medscape.com/viewarticle/927882

Mar 30th, 2020 - Alirocumab achieved a mean 63-mg/dL reduction in LDL cholesterol in the ODYSSEY HoFH study, the largest-ever randomized, placebo-controlled clinical trial of lipid-lowering in adults with homozygous familial hypercholesterolemia (HoFH), Dirk Blom,...

New Lipid-lowering Drug Class Slashes LDL in HoFH Patients
https://www.medscape.com/viewarticle/927862

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a "remarkable" and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Monthly intravenous ...

New lipid-lowering drug class slashes LDL in HoFH patients
https://www.mdedge.com/fedprac/article/219837/lipid-disorders/new-lipid-lowering-drug-class-slashes-ldl-hofh-patients?channel=53
Mitchel L. Zoler

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a “remarkable” and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Dr.

Genetic Testing Aids Diagnosis of Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/927467

Mar 24th, 2020 - NEW YORK (Reuters Health) - Adding genetic testing to the evaluation of patients at risk of familial hypercholesterolemia (FH) significantly increases the number of individuals diagnosed, according to a retrospective study. "My main hope is that o...

ORION: Inclisiran Phase 3 Trials Published
https://www.medscape.com/viewarticle/927107

Mar 17th, 2020 - Three phase 3 trials of the novel small-interfering RNA (siRNA) agent inclisiran (The Medicines Company) have been published, all showing an approximate halving of LDL cholesterol levels with the drug, which is given just twice a year by subcutane...

see more →

Patient Education  4 results see all →